Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

To compare the cardiac and renal impacts of GLP-1 receptor agonists vs. other oral hypoglycemic agents — specifically dipeptidyl peptidase 4 (DPP4) inhibitors — for patients with systemic ...

The GLP-1 drugs are "truly causing a lot of disruption for the surgeons and for the programs, and for patients," Thomas Tsai, MD, a bariatric surgeon at Brigham and Women's Hospital in Boston, told ...

Users on TikTok have touted the benefits of taking berberine supplements, claiming benefits for weight loss, heart health and more. Do you need them?

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...